Hegde Considers Combination Regimens for NSCLC With PD-L1 Expression 1% or Higher
January 16th 2022During a Targeted Oncology live event, Aparna Hegde, MD, discussed the results of the KEYNOTE-189 study of pemetrexed and pembrolizumab, the KEYNOTE-042 study of single-agent pembrolizumab, and the CheckMate 227 study of nivolumab and ipilimumab in patients with non–small cell lung cancer.
Part 1: PARP Inhibition Recommendations in Advanced Ovarian Cancer
January 12th 2022During a live virtual event, Matthew L. Anderson, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for treating patients with advanced ovarian cancer using PARP inhibitors based on BRCA mutation status and other factors.
Kim Discusses Multiple Immunotherapy Trials in PD-L1–Expressing NSCLC
January 7th 2022During a Targeted Oncology Case-Based Roundtable event, Chul Kim, MD, MPH, assistant professor at Georgetown University, discussed immunotherapy options for patients with non–small cell lung cancer with PD-L1 expression.
Part 2: Experiences With Sacituzumab and Biomarkers for TNBC
December 31st 2021During a live virtual event, Joyce O'Shaughnessy, MD, discussed participants' experiences with the tolerability of sacituzumab govitecan in patients with metastatic triple-negative breast cancer. The participants also discussed their approaches to molecular testing for biomarkers at the time of disease relapse or progression.
Part 2: Tolerability of Immunotherapy plus TKI Inhibitors in RCC
December 27th 2021During a live virtual event, Sandy Srinivas, MD, discussed the tolerability of the tyrosine kinase inhibitor/immunotherapy combinations cabozantinib plus nivolumab and lenvatinib plus pembrolizumab, compared with the dual immunotherapy ipilimumab plus nivolumab.
Part 1: Real-World Experience With Dosing Lenvatinib/Pembrolizumab in RCC
December 20th 2021During a live virtual event, Sandy Srinivas, MD, discussed results from the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and the participants' experiences with the regimen including dose reductions needed by their patients across multiple cancer types.
Part 2: Rare Mutations and Non-Clinical Barriers for Molecular Testing in NSCLC
December 16th 2021During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.